Department of Health and Human Services August 11, 2022 – Federal Register Recent Federal Regulation Documents
Results 1 - 6 of 6
Findings of Research Misconduct
Findings of research misconduct have been made against Stuart G. Jarrett, Ph.D. (Respondent), former research-track assistant professor, Department of Toxicology and Cancer Biology and Markey Cancer Center, University of Kentucky (UK) College of Medicine. Respondent engaged in research misconduct under 42 CFR part 93 in research supported by U.S. Public Health Service (PHS) funds, specifically National Cancer Institute (NCI), National Institutes of Health (NIH), grants R01 CA131075 and T32 CA165990, National Center for Advancing Translational Sciences (NCATS), NIH, grant UL1 TR000117, and National Institute of Environmental Health Sciences (NIEHS), NIH, grant T32 ES007266. The administrative actions, including debarment for a period of four (4) years, were implemented beginning on July 18, 2022, and are detailed below.
Prospective Grant of Exclusive License, Inter-Institutional Agreement-Institution Lead: Multivalent Vaccines for Rabies Virus and Coronaviruses
The National Institute of Allergy and Infectious Diseases, an institute of the National Institutes of Health, Department of Health and Human Services, is contemplating the grant of an exclusive, sublicensable patent license to Thomas Jefferson University, located in Philadelphia, Pennsylvania to practice the inventions embodied in the patent applications listed in the Supplementary Information section of this notice.
Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Registration and Product Listing for Owners and Operators of Domestic Tobacco Product Establishments and Listing of Ingredients in Tobacco Products
The Food and Drug Administration (FDA) is announcing that a proposed collection of information has been submitted to the Office of Management and Budget (OMB) for review and clearance under the Paperwork Reduction Act of 1995 (PRA).
Prevention of Salmonella Enteritidis in Shell Eggs During Production, Storage, and Transportation (Layers With Access to Areas Outside the Poultry House): Questions and Answers Regarding the Final Rule; Guidance for Industry; Availability
The Food and Drug Administration (FDA or we) is announcing the availability of a final guidance for industry entitled ``Prevention of Salmonella Enteritidis in Shell Eggs During Production, Storage, and Transportation (Layers with Access to Areas Outside the Poultry House): Questions and Answers Regarding the Final Rule.'' The guidance is intended to provide information to egg producers on certain provisions contained in FDA's final rule entitled ``Prevention of Salmonella Enteritidis in Shell Eggs During Production, Storage, and Transportation'' (the egg rule) that reference the ``poultry house.'' Specifically, the document provides guidance to shell egg producers whose production systems provide laying hens with access to areas outside of a ``poultry house'' as that term is defined in the egg rule.
Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Substances Prohibited From Use in Animal Food or Feed; Animal Proteins Prohibited in Ruminant Feed
The Food and Drug Administration (FDA) is announcing that a proposed collection of information has been submitted to the Office of Management and Budget (OMB) for review and clearance under the Paperwork Reduction Act of 1995.
This site is protected by reCAPTCHA and the Google
Privacy Policy and
Terms of Service apply.
